Results 71 to 80 of about 2,738 (166)

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

[State of the art: lipoprotein apheresis]. [PDF]

Dtsch Med Wochenschr, 2023
Schatz U, Schettler VJJ, Julius U.
europepmc   +1 more source

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

[Correction: State of the art: lipoprotein apheresis]. [PDF]

Dtsch Med Wochenschr, 2023
Schatz U, Schettler VJJ, Julius U.
europepmc   +1 more source

Low-density lipoprotein apheresis is associated with removal of SARS-CoV-2 antibodies. [PDF]

Ther Apher Dial, 2022
Bertram S, Pfab T, Albert C, Schmidt S, Passfall J, Haesner M, Seidel M, Hölzer B, Seibert FS, Doevelaar A, Rohn B, Zgoura P, Babel N, Westhoff TH.   +13 more
europepmc   +1 more source

Comparison of plasma separation using centrifugation or filtration for MONET lipoprotein apheresis in patients with cardiovascular disease and severe dyslipidemia. [PDF]

Ther Apher Dial, 2022
Waitz G, Atiye S, Gauly A, Prophet H.
europepmc   +1 more source

Low-density lipoprotein apheresis shows a rapid response to proteinuria due to C3 glomerulonephritis: a case report and literature review

Renal Replacement Therapy
Background C3 glomerulonephritis (C3GN) is a rare renal disorder caused by dysregulation of the alternative complement pathway, resulting in abnormal C3 activation and deposition.
Hideki Matsumura, Yuko Fujii, Tomoko Tanaka, Maki Kagitani, Akira Ashida   +4 more
doaj   +1 more source

Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function. [PDF]

Ther Apher Dial, 2022
Muso E, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Saito T, Mune M, Sugiyama S, Iino Y, Hirano T, Hattori M, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Oda H, Mori K, Kimura H, Ito O, Nishiyama A, Maruyama S, Inagi R, Fujimoto S, Tsukamoto T, Suzuki Y, Honda H, Babazono T, Tsuruya K, Yuzawa Y.   +31 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics & Systems Pharmacology
Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH).
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Yuhuan Wang, Poulabi Banerjee, Robert Pordy, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +8 more
doaj   +1 more source

Switching from lipoprotein apheresis to evolocumab in FH siblings on hemodialysis: case reports and discussion. [PDF]

CEN Case Rep, 2021
Ishii T, Ogura M, Nakamori H, Hori M, Harada-Shiba M, Tamura K, Oyama K.   +6 more
europepmc   +1 more source